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Background: We aimed to establish a new approach for surveillance of cancer prevalence and survival in
China, based on the Medical-Insurance-System-based Cancer Surveillance System (MIS-CASS).
Methods: We constructed a standard procedure for data collection, cleaning, processing, linkage, verification,
analysis, and estimation of cancer prevalence and survival (including both actual observations and model
estimates) by conjoint use of medical insurance claims data and all-cause death surveillance data. As a proof-
of-principle study, we evaluated the performance of this surveillance approach by estimating the latest prev-
alence and survival for upper gastrointestinal cancers in Hua County, a high-risk region for oesophageal can-
cer in China.
Findings: In Hua County, the age-standardised relative 5-year survival was 39¢2% (male: 36¢8%; female:
43¢6%) for oesophageal cancer and 33¢3% (male: 29¢6%; female: 43¢4%) for stomach cancer. For oesophageal
cancer, better survival was observed in patients of 4564 years compared with national average estimates,
and women of <75 years had better survival than men. The 5-year prevalence rate in Hua County was 99¢8/
100,000 (male: 105¢9/100,000; female: 93¢3/100,000) for oesophageal cancer and 41¢5/100,000 (male: 57¢4/
100,000; female: 24¢5/100,000) for stomach cancer. For both of these cancers, the prevalence burden peaked
at 6579 years. The model estimates for survival and prevalence were close to the observations in real inves-
tigation, with a relative difference of less than 4¢5%.
Interpretation: This novel approach allows accurate estimation of cancer prevalence and survival with a short
delay, which has great potential for regular use in general Chinese populations, especially those not covered
by cancer registries.
Funding: The National Key R&D Program of China (2016YFC0901404), the National Science & Technology
Fundamental Resources Investigation Program of China (2019FY101102), the National Natural Science Foun-
dation of China (82073626), the Taikang Yicai Public Health and Epidemic Control Fund (TKYC-GW-2020),
the Beijing-Tianjin-Hebei Basic Research Cooperation Project (J200016), and the Digestive Medical Coordi-
nated Development Center of Beijing Hospitals Authority (XXZ0204).
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In addition to incidence and mortality, prevalence and survival
figures are also important components in cancer surveillance.Prevalence measures the burden of cancer in a given population at a
particular time, thus providing crucial evidence for medical resource
allocation [1]. In general, estimation of cancer prevalence includes
individuals diagnosed with cancer within the last five years who are
still alive at the time of study. Those who were diagnosed at an earlier
time are usually assumed to be “cured” as their death rates tend to be
similar to those in the general population [2]. Population-level sur-
vival of cancer patients, which is commonly estimated at five years,
Research in context
Evidence before this study Population-level cancer surveil-
lance of prevalence and survival is crucial for establishing poli-
cies regarding medical resource allocation and strategies for
prevention and control. Estimating cancer prevalence and sur-
vival currently relies on population-based cancer registries
(PBCR). However, in China the population coverage of PBCRs is
still low due to the vast territory of this country, its huge popu-
lation, and limited resources (we searched PubMed and Google
Scholar for articles published before Jun 1, 2020, without lan-
guage restriction, using the terms “relative 5-year survival”, “5-
year relative survival”, “prevalence”, “cancer surveillance”,
etc.). We previously established a cancer incidence surveillance
approach based on claims data frommedical insurance systems,
but whether this methodology can be extended to cancer prev-
alence and survival surveillance is as yet undetermined.
Added value of this study For the first time, we conducted
an empirical study in a high-risk region for oesophageal cancer
in China which is not covered by PBCRs, and evaluated the per-
formance of cancer prevalence and survival surveillance based
on medical insurance claims data together with death surveil-
lance data. Results of this study demonstrated that these two
kinds of health-related big data can be used jointly to estimate
cancer prevalence and survival in a regular and timely manner
in this area.
Implications of all the available evidence This new
approach to surveillance of cancer prevalence and survival
based on health-related big data has potential for adoption in
broader areas not covered by PBCRs, and holds promise for
reform of cancer surveillance methodology in China.
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sure for evaluation of the performance of a health care system and
preventive programmes [3]. In most cases, accurate and up-to-date
estimation of prevalence and survival relies upon the availability of
high-quality population-based cancer registries (PBCR) and death
surveillance systems [3,4].
In China, cancer registration was launched in the 1950s, and a
total of 574 cancer surveillance points had been established by 2019,
which were located primarily in economically developed areas or in
regions of high-risk for specific cancers [57]. Nevertheless, data for
only 36 of these surveillance points covering 5% of the total national
population, were considered to be of sufficient high quality for inclu-
sion in Cancer Incidence in Five Continents [8,9]. In addition, the
annual reports of the National Cancer Center in China provide only
cancer incidence and mortality. For estimation of cancer deaths, data
are obtained mainly through linkage with the death surveillance sys-
tem, which was established in the 1950s and is currently operated by
the Chinese Center for Disease Control and Prevention. This system
contains 605 surveillance sites and covers 24¢3% of the total popula-
tion of China [10,11]. Thus far there is no surveillance system that
regularly estimates and reports cancer survival and prevalence
in China.
To date, only two studies reporting nationwide estimates of can-
cer survival have been published in China. Both included data from a
network of 17 cancer registries located predominately in eastern
regions of China, and covered approximately 2% of the national popu-
lation [12,13]. The sole set of cancer prevalence statistics in China
thus far was reported for the year 2011, and this has been estimated
based on cancer incidence data from 177 cancer registries and sur-
vival data from 17 cancer registries [14].
In the mode of PBCRs, current surveillance of cancer prevalence
and survival in China has encountered insurmountable barriers. First,population coverage cannot be increased rapidly as it cannot be car-
ried out in areas lacking PBCRs. Second, it is difficult to provide cancer
prevalence and survival estimates in a regular and timely manner,
since individual-level ascertainment of cancer cases is overwhelm-
ingly resource-intensive, and a 3-year delay is still incurred in the
current mode of cancer incidence surveillance.
In China, basic medical insurance systems are administered and
operated by the government, and cover over 95% of the national pop-
ulation. In a previous study, we established the Medical-Insurance-
System-based Cancer Surveillance System (MIS-CASS) and demon-
strated that this approach is capable of complete and accurate identi-
fication of incident cancer cases, and allows reporting cancer
incidence in a timely manner in two regions (six million residents
altogether) which are not covered by PBCRs in China [15].
In this study, we aimed to further this work by developing a stan-
dard procedure for cancer prevalence and survival surveillance by
bringing together data fromMIS-CASS and the death surveillance sys-
tem in Hua County, a high-risk area for oesophageal cancer in north-
ern China. As “proof of principle” we assessed the performance of
this novel approach by estimating the prevalence of, and survival
from upper gastrointestinal (GI) cancers (oesophageal cancer, non-
cardia gastric cancer, and cardia gastric cancer) in geographical areas
covered by two on-going large-scale population-based cohorts
[16,17].2. Methods
2.1. Study site
Hua County is a predominantly rural area in northern Henan Prov-
ince in China, which has 1¢07 million permanent residents and had a
per capita Gross Domestic Product of 24,585 Yuan (US $3715) in
2018 [1820]. The New Rural Co-operative Medical Care Scheme
(NCMS) is the sole medical insurance system for rural residents, and
this system has had coverage of 99% since 2010 [15]. The incidence
rate of oesophageal cancer ranked second among cancer types in Hua
County in 2018, and this rate was 2¢1 times as high as the national
level [15,21]. Over the past decade, we have carried out a series of
epidemiologic and etiologic studies of oesophageal cancer in Hua
County [16,17,22,23]. Due to the lack of PBCRs, accurate and updated
prevalence and survival data for upper GI cancers in this region
which is a typical high-risk region, have thus far not been reported.
However, such reporting is crucial for establishing medical resource
allocation policies and prevention and control strategies.2.2. Data collection and cleaning2.2.1. Incidence data for upper GI cancers
In this study, we extracted NCMS claims data for 20122019 from
the Healthcare Security Administration of Hua County in order to
definitively identify incident cases of upper GI cancer diagnosed
between 2014 and 2018 in the target villages of the Anyang Esoph-
ageal Cancer Cohort Study (AECCS) and Endoscopic Screening for
Esophageal Cancer in China (ESECC) cohorts. These villages included
834¢9 thousand rural residents and represented 66% of the total pop-
ulation of Hua County [16,17]. Ascertainment of incident cases based
on the MIS-CASS has been described in detail in our previous study
[15]. In brief, a 2-year time window (2012 and 2013) was adopted to
washout the prevalent cases (diagnosed before January 1, 2014) as
the incidence estimates were stable from the third year. Data from
January 1 to June 30 of 2019 were also included which allowed a
reimbursement delay of six months (the proportion of delays over six
months was lower than 2¢5%) [15]. In this study, non-cardia gastric
cancer and cardia gastric cancer were combined as stomach cancer.
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The vital status of all incident upper GI cancer patients was deter-
mined by passive record linkage with death surveillance data and
active follow-up.
We used all-cause death surveillance data between 2014 and
2019 from the Center for Disease Control and Prevention of Hua
County to identify deaths that might have occurred up to the end of
2019 among all the incident upper GI cancer patients in the target vil-
lages of AECCS and ESECC cohorts newly-diagnosed in 20142018.
The record linkage was performed using the unique personal identity
number as the index variable. Name, gender, birthdate, township,
and the village of origin were also used to assess the accuracy of the
linkage.
In addition, we also conducted active follow-up for all the identi-
fied cancer patients in the target villages in December of 2019 and
January of 2020. We first interviewed the village doctors in the target
villages and public health directors in township health centers
regarding all-cause death events among the cases of interest. We
then merged the death list from active interviews with the death list
from the death surveillance data. If no death was recorded in either
list (n = 906; 40¢2% of all cancer patients), or if it was recorded in one
list (n = 328; 14¢6% of all cancer patients), or recorded in both lists
but with different dates (n = 543; 24¢1% of all cancer patients), a
home visit or telephone contact with the next of kin was made to
confirm vital status and if the individual was dead, the date of death
was checked. Finally, the “Verified vital status data set” was deter-
mined for the subjects of the present study. A total of 18 well-trained
investigators in our team participated in the entire process of active
follow-up (1¢5 months), and they were required to regularly provideFig. 1. Procedure for survival and prevalence surveillance of upper GI cancers based on the M
NCMS=The New Rural Co-operative Medical Care Scheme. MIS-CASS=Medical-Insuran
Screening for Esophageal Cancer in China. AECCS=Anyang Esophageal Cancer Cohort Study.audio recordings of interviews for quality control. Informed consent
from all the interviewees were obtained during the active follow-up.
2.2.3. Data cleaning and processing
The procedure for cleaning and processing of the cancer incidence
and death data is depicted in Fig. 1. According to the MIS-CASS, a total
of 2534 incident oesophageal cancers and 1023 incident stomach
cancers occurred in Hua County from January 1, 2014 to December
31, 2018. Of these cases, 1623 oesophageal cancer cases and 649
stomach cancer cases from target villages were identified and
included in both passive and active follow-up. 1605 (98¢9%) of the
oesophageal cancer cases and 647 (99¢7%) of the stomach cancer
cases had definite vital status information, and were included in the
“Verified vital status data set”. Survival surveillance and prevalence
surveillance were then based on this data set.
2.3. Statistical analysis
2.3.1. Calculation of cancer survival
We chose median survival time, observed survival, and relative
survival as the main survival indicators. Median survival time was
defined as the shortest survival time for which the Kaplan-Meier sur-
vival function was no higher than 50%. Observed survival was calcu-
lated using the actuarial method. Expected survival was calculated
according to the Ederer II method using life tables stratified by gen-
der, age, and calendar year (Each investigated cancer case was
matched 1:1 with a cancer-free individual from the general popula-
tion in Hua County based on gender, age, and year of diagnosis) [24].
We divided observed survival by expected survival to obtain relativeIS-CASS and death surveillance data in Hua County, China.
ce-System-based Cancer Surveillance System. GI=gastrointestinal. ESECC=Endoscopic
4 H. Tian et al. / EClinicalMedicine 33 (2021) 100756survival. Compared to observed survival, relative survival better
measures the excess mortality experienced by cancer patients [24].
To further consider comparability of survival among patient groups
in different periods and regions, we categorized cancer cases into five
age groups (044, 4554, 5564, 6574, and 7599 years), and cal-
culated age-standardised relative survival according to the Interna-
tional Cancer Survival Standard weights: 0¢07 (044 years), 0¢12
(4554 years), 0¢23 (5564 years), 0¢29 (6574 years), and 0¢29
(7599 years) [25]. Age standardization was carried out using the
Brenner and Hakulinen approach to overcome the practical difficul-
ties of age standardization due to lack of data in a single age group
[26]. In addition, the Kaplan-Meier method was used to compare
observed survival among groups, and Cox regression models
were used to calculate hazard ratios (HR) as well as 95% confidence
intervals.
2.3.2. Calculation of cancer prevalence
We estimated upper GI cancer prevalence in Hua County in 2018
by using two methods, namely the “indirect method” and the “direct
method”.
For the indirect method, the number of prevalent cases was esti-
mated from survival estimates and year-specific incident cases based
on the following formula:
Pk nð Þ ¼
Xn
i¼1
ICki  Ski i 0 ¢5ð Þ
where ICk is the number of incident cancer cases at age k in Hua County,
and Sk(t) is the observed survival at time t after diagnosis for cases diag-
nosed at age k [2]. The prevalence rate was calculated as the count of 5-
year prevalent cases in Hua County in 2018 divided by the total popula-
tion of Hua County in 2018. The assumptionsmade for estimating prev-
alence based on the indirectmethod included: (a) annual incident cases
occur at mid-year and (b) the curve of observed survival with a 6-
month time interval follows theWeibull distribution [4].
In the direct method, the cancer prevalence rate in Hua County
was represented by the prevalence estimates in the investigated
AECCS and ESECC target villages (66% of the total population in Hua
County). In brief, the prevalence rate was directly calculated as the
count of investigated cases newly-diagnosed in 20142018 who
were still alive at the end of 2018 divided by the corresponding popu-
lation in the target villages in 2018.
2.3.3. Imputation-based estimation of survival and prevalence for
overall cancer and common cancers
Through comparing the vital status information from passive link-
age with death surveillance data and that from active follow-up, weTable 1
Survival of upper GI cancer patients diagnosed in 20142018 in Hua Coun





All 23¢2 67¢7% 40¢6%
(65¢3, 69¢9) (38¢1, 4
Male 22¢0 67¢1% 39¢2%
(63¢9, 70¢1) (35¢7, 4
Female 24¢5 68¢3% 42¢4%
(64¢8, 71¢6) (38¢6, 4
Stomach
All 23¢2 69¢4% 38¢8%
(65¢7, 72¢8) (34¢6, 4
Male 22¢6 69¢8% 36¢0%
(65¢4, 73¢7) (31¢2, 4
Female 26¢3 68¢4% 46¢1%
(61¢0, 74¢7) (38¢1, 5
GI=gastrointestinal. CI=confidence interval.observed that 21¢7% cancer deaths were missed by the death surveil-
lance system, and there was no significant discrepancy in male and
female, young and old, or oesophageal cancer and stomach cancer
(Supplementary Table 1, Supplementary Fig. 1). Assuming that
under-reporting of death events occurred randomly, we used an
imputation-based method to estimate survival and prevalence of
overall cancer as well as common cancer types, based on county-
wide data for cancer incidence (20142018) and death (20142019).
In this regard, we imputed the under-reported dead cases through
random selection of 1121 ¢7%  1
  N “alive cases” (N is the number
of patients with the cancer of interest whose death was actually
recorded in the death surveillance system), using gender, cancer site
and the year of diagnosis as stratification variables. This imputation-
based approach was repeated 1000 times to estimate the survival
and prevalence of cancer overall and five cancer types with the high-
est incidence in Hua County [15].
Stata 15.0 and R statistics version 3.5.0 were used for all analysis
(strs in Stata was used for survival analysis).
2.4. Ethics committee approval
This study was approved by the Institutional Review Board of the
Peking University School of Oncology, China. Informed consent was
obtained from all the interviewees.
2.5. Role of the funding source
The funders of the study had no role in study design, collection,
analysis, and interpretation of data, or writing of the report. HT, ZH,
and YK had full access to all the data in the study, and the corre-
sponding authors were responsible for the decision to submit for
publication.
3. Results
3.1. Survival in upper GI cancers
In Hua County, the age-standardised relative 5-year survival was
39¢2% (male: 36¢8%; female: 43¢6%) for oesophageal cancer and 33¢3%
(male: 29¢6%; female: 43¢4%) for stomach cancer. The observed sur-
vival estimates were lower than the corresponding age-standardised
relative survival estimates for oesophageal cancer, but not for stom-
ach cancer (Table 1).
Older groups in this population showed poorer survival. For oeso-
phageal cancer, the combined relative 5-year survival for males and
females was 48¢2%, 51¢7%, 35¢5%, and 18¢9% for patients diagnosed at
ages 4554, 5564, 6574, and 7599 years respectively. Notably,ty, China.
CI) Age-standardised relative survival (95% CI)
5-year 1-year 3-year 5-year
31¢2% 70¢9% 46¢1% 39¢2%
3¢2) (28¢4, 34¢1) (68¢1, 73¢6) (42¢8, 49¢4) (35¢7, 42¢8)
28¢6% 69¢6% 44¢0% 36¢8%
2¢6) (24¢9, 32¢4) (65¢5, 73¢3) (39¢4, 48¢5) (32¢0, 41¢7)
34¢6% 74¢0% 50¢5% 43¢6%
6¢3) (30¢3, 38¢9) (70¢1, 77¢4) (45¢3, 55¢5) (37¢8, 49¢2)
32¢8% 68¢7% 38¢3% 33¢3%
2¢9) (28¢4, 37¢4) (64¢4, 72¢6) (33¢6, 42¢9) (28¢3, 38¢5)
28¢8% 69¢2% 35¢5% 29¢6%
0¢8) (23¢7, 34¢2) (63¢9, 73¢9) (30¢0, 41¢1) (23¢9, 35¢7)
43¢4% 67¢3% 45¢6% 43¢4%
3¢8) (35¢0, 51¢5) (59¢3, 74¢2) (36¢9, 53¢9) (34¢1, 52¢5)
Fig. 2. Relative 5-year survival (with 95% CI) for oesophageal cancer by age group at
diagnosis (4599 years) in Hua County, China, 20142018.
CI=confidence interval.
ySource: Adapted from Zeng et al. [12].
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Hua County than the reported national average estimates for patients
diagnosed in 20122013 and followed up to 2015 (Fig. 2). For stom-
ach cancer, relative 5-year survival was 47¢9%, 49¢4%, and 38¢3% for
patients of 4554 years, 5564 years, and 6574 years (no estimate
was available for patients older than 74 because the longest individ-
ual follow-up time after diagnosis was less than five years), similar to
the national average estimates for patients diagnosed in 20122013
(Supplementary Fig. 2).3.2. Age-gender interaction of survival of upper GI cancers
Overall, survival of oesophageal cancer was better in women than
in men (HRadjusted for age=0¢81, 95% CI: 0¢710¢92). We further strati-
fied patients into three age groups at diagnosis, and the adjustedFig. 3. Kaplan-Meier survival curves (with 95% CI) for oesophageal cancer by age group at dia
HR=hazard ratio (adjusted for age). CI=confidence interval.female-to-male HRs were 0¢65 (95% CI: 0¢480¢87), 0¢73 (95% CI:
0¢600¢90), and 0¢96 (95% CI: 0¢781¢18) for age groups 064,
6574, and 7599 years respectively (pinteraction=0¢005) (Fig. 3). A
similar trend was also found in stomach cancer patients, although
the p value for interaction was not significant (Supplementary Fig. 3).3.3. Prevalence of upper GI cancers
According to the indirect method, the 5-year prevalence rate for
oesophageal cancer was 99¢8/100,000 (male: 105¢9/100,000; female:
93¢3/100,000; male-to-female ratio: 1¢1). For stomach cancer, the 5-
year prevalence rate was 41¢5/100,000, with a larger gender discrep-
ancy than oesophageal cancer (male: 57¢4/100,000; female: 24¢5/
100,000; male-to-female ratio: 2¢3). The prevalence/incidence ratio
was 2¢7 for oesophageal cancer and 2¢4 for stomach cancer (Table 2)
[15]. For both oesophageal cancer and stomach cancer, the absolute
number of prevalent cases peaked at 6574 years, while the age-spe-
cific prevalence rate peaked at 7079 years (Fig. 4). Among all 5-year
prevalent cases of upper GI cancers in 2018, patients who had been
diagnosed 23 years earlier constituted the largest group (Supple-
mentary Fig. 4). Similar results were observed with the direct method
(Supplementary Table 2).3.4. Imputation-based estimations of survival and prevalence for overall
cancer and common site-specific cancers
Based on the county-wide dataset of cancer incidence and death,
as well as a 21¢7% under-reporting rate of death surveillance system,
we re-estimated relative 5-year survival and prevalence rates for
oesophageal cancer and stomach cancer using an imputation-based
method, and observed results similar to the above real-world results
(oesophageal cancer survival: 39¢6% vs. 39¢2%; stomach cancer sur-
vival: 34¢8% vs. 33¢3%; oesophageal cancer prevalence rate: 103¢1/
100,000 vs. 99¢8/100,000; stomach cancer prevalence rate: 40¢9/
100,000 vs. 41¢5/100,000). Based on this, we further estimated sur-
vival and prevalence for other cancers in Hua County. The overallgnosis in Hua County, China, 20142018.
Table 2
Prevalence of upper GI cancers in Hua County, China, 2018 (Indirect Method).
Site Gender Prevalent cases in Hua County 5-year prevalence rate [1/105 (95% CI)] New cases in Hua County in 2018 Incidence rate (1/105) P:I ratio
1 year 3 years 5 years
Oesophagus
All 379 885 1264 99¢8 (94¢4, 105¢5) 474 37¢4 2¢7
Male 219 490 694 105¢9 (98¢2, 114¢1) 277 42¢3 2¢5
Female 160 395 570 93¢3 (85¢8, 101¢3) 197 32¢2 2¢9
Stomach
All 180 396 525 41¢5 (38¢0, 45¢2) 218 17¢2 2¢4
Male 137 291 376 57¢4 (51¢7, 63¢5) 167 25¢5 2¢2
Female 43 105 150 24¢5 (20¢8, 28¢8) 51 8¢3 2¢9
GI=gastrointestinal. P:I = 5-year cancer prevalence to incidence. CI=confidence interval.
6 H. Tian et al. / EClinicalMedicine 33 (2021) 100756relative 5-year survival for cancer patients in Hua County was esti-
mated as 44¢5% (95% CI: 42¢946¢0), and the overall 5-year preva-
lence rate for cancer patients in Hua County was estimated as 585¢1/
100,000. The relative 5-year survival of common cancers in Hua
County ranged from 17¢5% (liver cancer in men) to 83¢9% (thyroid
cancer in women). The prevalence rate of common cancers in Hua
County ranged from 22¢1/100,000 (liver cancer in men) to 175¢8/
100,000 (female breast cancer). (Supplementary Table 3)
4. Discussion
Comprehensive surveillance of cancer incidence, prevalence and
survival is critical for optimizing strategies for cancer prevention
and control, and for efficiently allocating medical resources, as well
as for evaluating the performance of clinical treatment. However,
under the current situation in China, it is impossible to obtain esti-
mates of cancer prevalence and survival in areas not covered byFig. 4. Age-specific 5-year prevalence for upper GI cancers in Hua County, China, 2018.
GI=gastrointestinal.PBCRs. In fact, even in areas covered by PBCRs, it is difficult to pro-
duce up-to-date estimates in a regular and timely manner. In this
study, we have established a new approach to surveillance for can-
cer prevalence and survival based on population-level medical
insurance claims data and death surveillance data. For the first
time, we have reported the survival and prevalence of upper GI
cancers in an area which is high-risk for oesophageal cancer that is
not covered by PBCRs in China, and in addition we have estimated
survival and prevalence of overall cancer and common cancer types
using an imputation-based method. This study is one extension of
our MIS-CASS which was primarily applicable to cancer incidence
surveillance, and this approach can be regularly carried out with
broader population coverage in China, given that basic medical
insurance covers 95% of the national population, and incident can-
cer cases can be ascertained using MIS-CASS with only a short
time lag (~ six months) between a cancer diagnosis and its regis-
tration in the insurance database [15].
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oesophageal cancer, however no cancer survival statistics have been
reported locally due to the lack of cancer registries [1517]. Accord-
ing to our estimation in this study, the age-standardised relative 5-
year survival of oesophageal cancer in Hua County is 39¢2%, which is
notably higher than the average national level (30¢3%), especially in
the 4564 age group (relative 5-year survival ratio: 1¢3) [12]. This
may be explained in part by a series of screening programmes con-
ducted in this local area. In 2006, we initiated the AECCS and over
8000 residents aged 2565 years from Hua County underwent endo-
scopic screening for upper GI cancers [16,27]. In 2012, we initiated
the ESECC randomised controlled trial in Hua County and a total of
15,188 local residents aged 4569 years were screened endoscopi-
cally from 2012 to 2016 [17]. In addition, after 2011, Hua County has
been covered by the Screening, Early Diagnosis, and Early Treatment
program for upper GI cancers (15002000 enrollees annually, 4069
years), which is subsidized by the central government of China
[28,29]. These cancer screening programmes promote detection,
diagnosis, and treatment of early oesophageal cancer cases, and this
may have in part contributed to the notably better survival of oeso-
phageal cancer in the corresponding age group locally. However, it
must be noted that whether early screening efforts do indeed
improve the prognosis of oesophageal cancer cannot be answered by
observing the survival of cancer patients per se due to lead-time and
length-time bias, and population-based randomised controlled trials
are still warranted [17,27,30]. Unlike oesophageal cancer, the survival
of stomach cancer in Hua County (33¢3%) is similar to the average
level for China (35¢1%) [12]. Given that stomach cancer is not a high-
risk cancer in Hua County, the protective effect of upper GI tract
endoscopy on stomach cancer might not be as obvious as that for
oesophageal cancer at the population level.
Overall, upper GI cancer cases in males had a higher mortality risk
than those in females, which is consistent with the general pattern in
China [12]. However, stratified analysis by age demonstrated notable
heterogeneity in the association of gender and mortality risk for
upper GI cancers across age groups at diagnosis, especially for oeso-
phageal cancer (Fig. 3, Supplementary Fig. 3). For oesophageal cancer
patients diagnosed before the age of 75, the mortality risk in males
was 1¢41¢5 times as high as that in females, but no appreciable dis-
crepancy in mortality risk in male versus female patients was
observed in patients diagnosed after 75. This indicates male patients
and female patients are comparably susceptible to mortality in older
groups, where age rather than gender serves as the determinant of
cancer prognosis.
The oesophageal cancer prevalence in Hua County is 2¢6 times as
high as the national level (Table 2) [14]. This may largely be explained
by the fact that Hua County is a high-risk area for oesophageal cancer,
with an incidence 2¢1 times as high as national level [15,17]. For both
oesophageal cancer and stomach cancer, the prevalence rate in this
study was extremely low in individuals of less than 50 years, but
increased with age and peaked in the age group 7079 years. This
pattern of age-specific prevalence rates in upper GI cancers is consis-
tent with the overall trend of age-specific incidence rates (Supple-
mentary Fig. 5) [15]. For both the prevalence count and prevalence
rate, the burden of upper GI cancers was the greatest in individuals
aged 6579 years, who generally suffer from more health inequal-
ities in rural China [31]. This suggests that adjustments should be
made in terms of medical resource allocation and medical insurance
policies to meet the needs of patients in this age group.
As one of the important preconditions for this new approach to
surveillance, the evaluation of quality of local death surveillance data
was conducted through comparing the performance of passive and
active follow-up for upper GI cancers. We observed that the Hua
County death registry reported death events with moderate sensitiv-
ity (78¢3%) and high specificity (99¢1%), and no significant discrep-
ancy in the rate of under-reporting was found by gender, age group,or cancer site (Supplementary Table 1, Supplementary Fig. 1). As
such, we further conducted a simulation analysis (repeated 1000
times) to estimate the survival and prevalence of overall cancer and
five major cancers in Hua County, by randomly imputing the under-
reported deaths from the “alive” patients. The 1000 imputation-
based estimates for each common cancer were within a relatively
narrow range (mostly <10%), and the median estimates for both
oesophageal cancer and stomach cancer were very close to the esti-
mates which resulted from real investigation, with a relative differ-
ence of less than 4¢5% (Table 1, 2, Supplementary Table 2, 3,
Supplementary Fig. 6). However, there is a caveat in applying the
imputation-based approach since under-reporting rates of death may
vary in different cancer types. Given that under-reporting is a com-
mon issue for death surveillance system in China (12%17% at the
national level), we strongly recommend assessing the data quality of
a given local death surveillance system before using this method
[11,32]. Active follow-up of a representative sample of cancer
patients would allow estimation of the level of under-reporting in
the local death surveillance system, and the extent to which it varies
by critical factors such as cancer site and patient characteristics such
as gender, age, and area of residence.
Our study showed that the proposed MIS-CASS approach for sur-
veillance of cancer prevalence and survival has three main strengths.
First, its coverage is high, as both the medical insurance system (e.g.
NCMS) and the death surveillance system which are the two data
sources used to determine the occurrence and endpoint of a cancer
case, covered the whole population under study [15]. Over 99% (668/
674) of the villages we investigated in this study were target villages
in the ESECC trial which were randomly selected from the ~1000 vil-
lages in Hua County, and this further ensures the representativeness
of the study sample [17]. Second, with use of the MIS-CASS approach,
where incident cancer cases can be identified with a delay of only six
months, up-to-date prevalence and survival estimates can be pro-
duced and reported in almost real-time. This would greatly facilitate
timely assessment of cancer burden and cancer-specific prognosis, as
well as performance of health care programmes by the government.
Third, the prevalence and survival estimates for upper GI cancers in
this study are robust, given that similar results were observed with
both the indirect and direct methods (e.g. the relative difference in
prevalence rates was less than 10%), and similar results were also
found in both the real-world data-based and imputation-based
approaches (shown in Results). Based on these, this new approach to
cancer prevalence and survival surveillance has potential for regular
use in wider administrative areas including those not covered by
PBCRs.
However, this study also has limitations. Although rural Hua
County has a population of 1¢27 million and the villages we investi-
gated included as many as 835 thousand individuals, this is nonethe-
less a single-center study conducted at the county level. It is
necessary to conduct comparative studies in areas covered by high-
quality PBCRs in China to further evaluate the performance of this
novel approach. Given that cancer is still a relatively rare disease
even in a high-risk area, estimates of the prevalence and survival of
low incidence cancer types (such as nasopharyngeal cancer and mel-
anoma of the skin) may not be statistically robust [15]. This concern
could be addressed by using this method in a larger area with a larger
population. Moreover, caution must be exercised when applying this
approach to surveillance in areas with different levels of socioeco-
nomic development, and evaluation of the accuracy and complete-
ness of local death surveillance data is needed.
The advent of the “big data” era and the increasing availability of
electronic health records, has resulted in a promise of a real-time
multi-dimensional cancer surveillance system with a wider popula-
tion coverage. This study, together with our previous report, describe
a novel comprehensive approach to surveillance of cancer in China
which incorporates three critical dimensions incidence, prevalence,
8 H. Tian et al. / EClinicalMedicine 33 (2021) 100756and survival  by bringing together multiple “big” routine data sour-
ces including medical insurance claims data and death surveillance
data [15]. The latter covers only 24% of the national population, but
the Healthy China Programme (20192030) has recently emphasized
the urgent need to further expand death surveillance in China with
the ultimate goal of establishing a nation-wide surveillance system.
In short, this newly proposed cancer surveillance approach  which
provides valid and up-to-date cancer incidence, prevalence, and sur-
vival estimates in a timely way  offers great potential for being
scaled up for use in much wider geographical areas, particularly in
those that are not currently covered by PBCRs at a relatively low cost
by relying on existing data sources.Declaration of Competing Interest
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